These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23393324)

  • 1. Fenbendazole as a potential anticancer drug.
    Duan Q; Liu Y; Rockwell S
    Anticancer Res; 2013 Feb; 33(2):355-62. PubMed ID: 23393324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies.
    Duan Q; Liu Y; Booth CJ; Rockwell S
    J Am Assoc Lab Anim Sci; 2012 Mar; 51(2):224-30. PubMed ID: 22776123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.
    Kim EY; Liu Y; Akintujoye OM; Shyam K; Grove TA; Sartorelli AC; Rockwell S
    Radiat Res; 2012 Sep; 178(3):126-37. PubMed ID: 22862779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of 5-thio-D-glucose to alter cell survival in irradiated or unirradiated EMT6 tumors.
    Rockwell S; Schulz RJ
    Radiat Res; 1984 Dec; 100(3):527-35. PubMed ID: 6505142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication.
    Dogra N; Mukhopadhyay T
    J Biol Chem; 2012 Aug; 287(36):30625-40. PubMed ID: 22745125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies of porfiromycin as an adjunct to radiotherapy.
    Rockwell S; Keyes SR; Sartorelli AC
    Radiat Res; 1988 Oct; 116(1):100-13. PubMed ID: 3186923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
    Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.
    Rockwell S; Liu Y; Seow HA; Ishiguro K; Baumann RP; Penketh PG; Shyam K; Akintujoye OM; Glazer PM; Sartorelli AC
    Int J Radiat Biol; 2012 Mar; 88(3):277-85. PubMed ID: 22111842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicities of mitomycin C and x rays to aerobic and hypoxic cells in vitro.
    Rockwell S
    Int J Radiat Oncol Biol Phys; 1982 Jun; 8(6):1035-9. PubMed ID: 6809713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.
    Rockwell S; Keyes SR; Loomis R; Kelley M; Vyas DM; Wong H; Doyle TW; Sartorelli AC
    Cancer Commun; 1991 Jun; 3(6):191-8. PubMed ID: 2049227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
    Rockwell S; Kelley M
    Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of edotecarin in breast carcinoma models.
    Ciomei M; Croci V; Stellari F; Amboldi N; Giavarini R; Pesenti E
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):229-35. PubMed ID: 17089166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
    Rockwell S; Kelley M
    Radiother Oncol; 1996 Apr; 39(1):65-71. PubMed ID: 8735495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
    Keyes SR; Heimbrook DC; Fracasso PM; Rockwell S; Sligar SG; Sartorelli AC
    Adv Enzyme Regul; 1985; 23():291-307. PubMed ID: 3934922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diarylsulfonylureas and radiotherapy. I. In vitro studies with N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea (Sulofenur).
    Rockwell S; Grindey GB
    Cancer Commun; 1991 Apr; 3(4):103-8. PubMed ID: 2025495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
    Rockwell S
    J Natl Cancer Inst; 1983 Oct; 71(4):765-71. PubMed ID: 6413743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teaching an old dog new tricks: The case of Fenbendazole.
    Vlachou I; Parsonidis P; Mamagkaki A; Bouris I; Papasotiriou I
    Cancer Treat Res Commun; 2022; 32():100601. PubMed ID: 35780728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with radiation, mitomycin C, and 5-fluorouracil in EMT6 tumors.
    Rockwell S
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):127-33. PubMed ID: 8270433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.